This podcast series from the Academy's Committee on Aging features leading experts who discuss clinical experiences and the differences in caring for older adults. In today's podcast, participants discuss how to approach retinal vein occlusions in the scope of other diseases particular to the aging adult, how diagnosis is best established for a central retinal vein occlusion, and how to evaluate a patient over a course of long-term care. Also discussed is the use of anti-VEGF agents and intraocular steroids for the treatment of patients with macular edema related to vein occlusion. Finally, we consider what symptomatic factors may influence the clinician to observe these patients or instead use focal laser.

Financial Disclosures: Dr. Bressler discloses that he receives consulting fees or grant support from Abbott Medical Optics, Allergan, Bausch & Lomb Surgical, Carl Zeiss Meditec, EMMES Corporation, ForSight Labs, Genentech, Lumenis, Notal Vision, Novartis Pharmaceuticals, Othera Pharmaceuticals, QLT Phototherapeutics, Regeneron, and Steba Biotech. Dr. Haller discloses that she receives consulting fees from Allergan, Genentech, Macusight, Optimedica, and Thrombogenics. Dr. Ip discloses that he receives consulting fees or grant support from Allergan, Genentech, Notal Vision, QLT Phototherapeutics, Regeneron, and Sirion. Dr. Schachat discloses that he receives consulting fees from Genentech and Neovista.